<DOC>
	<DOCNO>NCT00806546</DOCNO>
	<brief_summary>This study use open-label design evaluate safety NP101 . Adult subject meet enrollment criterion treat NP101 ( sumatriptan succinate iontophoretic transdermal patch ) acute migraine attack 12 month period .</brief_summary>
	<brief_title>An Open-Label Study Evaluate Safety NP101 Treatment Acute Migraine Over Twelve Months</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Subject adult male female , age range 18 year 65 year . Subject diagnosis migraine headache , without aura , define ICHDII diagnosis make age 50 . Subject experience mild severe headache migraine attack base subject testimony . Subject least one year history migraine base upon subject testimony . Subject typically experience least two migraine headache per month base subject testimony . Subject judge good health , base upon result medical history , physical examination , vital sign , ECG laboratory profile . Subjects clinically significant abnormal laboratory parameter , vital sign ECG parameter order qualify enrollment . Female subject childbearing potential ( surgically sterile 2 year postmenopausal ) must negative pregnancy test screen prior enrollment . Subject must negative drug screen . Subject must capable read understand either English Spanish subject information material . Be able successfully apply practice patch , carryout subject procedure , able voluntarily sign date IC agreement approve IRB . Subject least two acceptable patch application site ( upper arm upper thigh ) relatively hair free scar , tattoo , scratch bruise . In investigator 's opinion subject stable medication regimen . Subject 15 headache day per month three month prior screen . Subject suspect confirmed cardiovascular disease contraindicates study participation . Subject history epilepsy condition associate lowered seizure threshold . Subject Raynaud 's disease . Subject history basilar hemiplegic migraine . Subject history ( within 1 year ) current evidence drug alcohol abuse dependence . Subject take nontriptan serotonergic drug include SSRIs ( include Wellbutrin ) , SNRIs , TCAs , MAOIs preparation contain St. John 's Wort within 1 month prior screen and/or plan start medication study . Subject unwilling discontinue use PD5 inhibitor ( e.g . Viagra® , Levitra® , Cialis® ) Final Visit . Subject history significant allergy hypersensitivity component study patch use study . Subject generalize skin irritation disease include eczema , psoriasis , melanoma , contact dermatitis would affect transdermal absorption sumatriptan / affect subject ability ass skin irritation . Subject clinically significant abnormal laboratory parameter , vital sign ECG parameter . Subject know hepatitis B , hepatitis C HIV positive . Subject diagnosis bipolar disorder current major depressive disorder , medical psychiatric condition , investigator 's opinion would make subject unsuitable enrollment / participation study . Subject hepatic dysfunction define SGOT/AST SGPT/ALT ≥ 2 time upper limit normal ( ULN ) range , alkaline phosphatase total bilirubin ≥ 1.5 time ULN range opinion Investigator subject 's history , physical examination laboratory test suggest hepatic dysfunction . Female subject pregnant , breast feeding , childbearing potential , use unwilling use effective form contraception study period 30 day follow dosing . Subject known history failure respond sumatriptan ( ineffective poorly tolerate ) . Subject participate clinical study within 30 day screen plan participate another clinical study . Subject previously enrol NP101008 . Subject electrically sensitive ( e.g. , prior iontophoresis adverse outcome relate current deliver device ) electrically sensitive support system ( e.g. , pacemaker ) medical condition investigator 's opinion would make subject unsuitable enrollment study . Subject consider investigator NuPathe , reason , unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>